These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
154 related articles for article (PubMed ID: 26245737)
21. Stimulatory autoantibodies to the PDGF receptor: a link to fibrosis in scleroderma and a pathway for novel therapeutic targets. Gabrielli A; Svegliati S; Moroncini G; Luchetti M; Tonnini C; Avvedimento EV Autoimmun Rev; 2007 Dec; 7(2):121-6. PubMed ID: 18035321 [TBL] [Abstract][Full Text] [Related]
22. Autoantibody to RNA polymerase I in scleroderma sera. Reimer G; Rose KM; Scheer U; Tan EM J Clin Invest; 1987 Jan; 79(1):65-72. PubMed ID: 2432091 [TBL] [Abstract][Full Text] [Related]
23. Diagnosis of Systemic Sclerosis Based on Raynaud's Phenomenon, Capillaroscopy Findings, and Autoantibodies in the Absence of Sclerodactyly. Druyan A; Lidar M Isr Med Assoc J; 2018 Oct; 20(10):658. PubMed ID: 30324790 [No Abstract] [Full Text] [Related]
24. Functional autoantibodies in systemic sclerosis. Günther J; Rademacher J; van Laar JM; Siegert E; Riemekasten G Semin Immunopathol; 2015 Sep; 37(5):529-42. PubMed ID: 26292621 [TBL] [Abstract][Full Text] [Related]
25. Autoantibodies to bactericidal/permeability-increasing protein and cathepsin G in systemic sclerosis. Grypiotis P; Cozzi F; Ruffatti A J Rheumatol; 2004 Jul; 31(7):1468-9. PubMed ID: 15229985 [No Abstract] [Full Text] [Related]
33. Anti-topoisomerase I autoantibodies in systemic sclerosis. Czömpöly T; Simon D; Czirják L; Németh P Autoimmun Rev; 2009 Jul; 8(8):692-6. PubMed ID: 19393194 [TBL] [Abstract][Full Text] [Related]
34. Clinical significance of anti-Ku autoantibodies--a serologic marker of overlap syndrome? Mimori T Intern Med; 2002 Dec; 41(12):1096-8. PubMed ID: 12521194 [No Abstract] [Full Text] [Related]
35. Brief Report: Anti-RNPC-3 Antibodies As a Marker of Cancer-Associated Scleroderma. Shah AA; Xu G; Rosen A; Hummers LK; Wigley FM; Elledge SJ; Casciola-Rosen L Arthritis Rheumatol; 2017 Jun; 69(6):1306-1312. PubMed ID: 28217959 [TBL] [Abstract][Full Text] [Related]
36. Investigation of myositis and scleroderma specific autoantibodies in patients with lung cancer. Betteridge ZE; Priest L; Cooper RG; McHugh NJ; Blackhall F; Lamb JA Arthritis Res Ther; 2018 Aug; 20(1):176. PubMed ID: 30092841 [TBL] [Abstract][Full Text] [Related]
37. Antitopoisomerase and anticentromere antibodies in the sclerodermatosus complex. Kallenberg CG Clin Rev Allergy; 1994; 12(3):221-35. PubMed ID: 7804956 [No Abstract] [Full Text] [Related]
38. Resolution of paraneoplastic PM/Scl-positive systemic sclerosis after curative resection of a pancreatic tumour. Bruni C; Lages A; Patel H; Nihtyanova SI; Green B; AbuHilal M; Harvey J; Ong VH; Matucci Cerinic M; Derrett-Smith E; Denton CP Rheumatology (Oxford); 2017 Feb; 56(2):317-318. PubMed ID: 27803307 [No Abstract] [Full Text] [Related]
39. The many faces of scleroderma. Steen VD Rheum Dis Clin North Am; 2008 Feb; 34(1):1-15; v. PubMed ID: 18329529 [TBL] [Abstract][Full Text] [Related]
40. Antibodies to high mobility group proteins in systemic sclerosis. Ayer LM; Sénecal JL; Martin L; Dixon GH; Fritzler MJ J Rheumatol; 1994 Nov; 21(11):2071-5. PubMed ID: 7869312 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]